MedTrace Logo

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

NCT06949956 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2025-05-02

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.

Participants who are already taking fingolimod as part of their regular medical care for MS will answer questions about their medical history for the past 1 year and for their status for the next 2 years.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Sponsors & Collaborators

  • AHEPA University Hospital

    collaborator OTHER

  • Elpen Pharmaceutical Co. Inc.

    lead INDUSTRY

Principal Investigators

  • Nikolaos Grigoriadis, MD · AHEPA University Hospital of Thessaloniki, Greece

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-12-31
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949956 on ClinicalTrials.gov